HeartBeam Completes Enrollment for HEADSTART-ACS Study
HeartBeam, Inc. has successfully completed patient enrollment for its 486-patient HEADSTART-ACS study ahead of the original schedule.
Stocks · News reference
HeartBeam Completes Enrollment Ahead Of Schedule In 486-Patient HEADSTART-ACS Study
HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most populous country, representing strategically significant market of 288 million peopleData analysis is
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HeartBeam Named Contributing Partner In Launch Of EXIT-CVD Research Project, Co-Funded By European Union Innovative Health Initiative And Industry Partners
HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortiumHeartBeam will lead the HEART-CHECK Study, one of the project’s 22 studiesHEART-CHECK
HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System
HeartBeam secures an expedited FDA designation for its 3D ECG at-home heart attack assessment tool, paving the way for rapid clinical trials.